%0 Journal Article
%T Going the distance: reviewing antipsychotic depot or long
%A Balaji Motamarri
%A Hannah Chu-Han Huang
%A Mark Taylor
%A Nancy Wang
%A Theo Theodoros
%J Australasian Psychiatry
%@ 1440-1665
%D 2018
%R 10.1177/1039856218758559
%X The aim of this study is to provide an opinion paper reviewing the role of depot or long-acting injectable (LAI) antipsychotic medications, with comments on individual newer LAIs such aripiprazole maintena and paliperidone palmitate. In particular, we share our recent experience of using paliperidone three-monthly LAI. We also reflect on the associated benefits and potential harms of LAIs, and when they may be used. LAI antipsychotics are an important and arguably under-utilised therapeutic option, particularly where medication adherence is a priority, and where an informed patient opts for this formulation. Paliperidone is the first three-monthly LAI antipsychotic, and as such represents a significant advance in the range of treatment choices
%K long-acting injectables
%K depot
%K antipsychotic
%U https://journals.sagepub.com/doi/full/10.1177/1039856218758559